Tinlarebant tablet is used for the treatment of geographic atrophy. Credit: CGN089 / Shutterstock.

Belite Bio has received approval from the Taiwan Food and Drug Administration (TFDA) to initiate the Phase III PHOENIX study of Tinlarebant (LBS-008) tablet for the treatment of geographic atrophy (GA).

The fixed-dose, randomised, double-masked, placebo-controlled study intends to assess the safety and efficacy of the orally administered Tinlarebant in patients with GA associated with Dry Age-related Macular Degeneration (Dry AMD).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Nearly 430 subjects will be enrolled and randomised in a 2:1 ratio to receive Tinlarebant or placebo.

In an ongoing two-year Phase II study in adolescents, atrophic retinal lesions were found to be reduced in Stargardt Disease (STGD1) patients administered with Tinlarebant. The treatment was compared to a natural history study of the disease (ProgStar).

In addition, a continued trend of slowing expansion of autofluorescence was observed.

See Also:

The company is also enrolling subjects for its Phase III DRAGON study of Tinlarebant in adolescent STGD1 patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Tinlarebant has been developed for reducing the accumulation of vitamin A-based toxins (bisretinoids), which cause STGD1 and contribute to dry AMD.

It reduces the serum retinol-binding protein 4 (RBP4) level, a carrier protein that delivers retinol from the liver to the eye.

The PHOENIX study of Tinlarebant has already been initiated in the US.

The therapy has also received Rare Pediatric Disease Designation and Fast Track Designation in the US, and Orphan Drug Designation in both Europe and the US for the treatment of STGD1.